Study summary · research use only
Anabolic therapies for osteoporosis
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses anabolic therapies for osteoporosis in humans, describing teriparatide as the first FDA-approved anabolic agent for the condition and noting its use in people at highest fracture risk, despite limitations of cost, delivery route, and treatment duration. The review states that available data show combination therapy with teriparatide and antiresorptive agents offers no added therapeutic advantage, but that treatment with an antiresorptive agent after teriparatide discontinuation is needed to prevent subsequent bone loss. It also notes that although pretreatment with bisphosphonates may somewhat reduce teriparatide's anabolic effect, meaningful gains in bone mineral density are still achieved, and states prior bisphosphonate use should not discourage clinicians from using teriparatide in select patients.
Abstract
As the first FDA-approved anabolic agent for osteoporosis, teriparatide has proven effective for people at highest risk of fracture, despite limitations of expense, route of delivery, and length of treatment. Available data show that combination therapy with teriparatide and antiresorptive agents does not offer a therapeutic advantage. However, treatment with an antiresorptive agent after teriparatide discontinuation is essential to prevent the ensuing bone loss. Although pretreatment with bisphosphonates may somewhat attenuate the anabolic effect of teriparatide, significant gains in bone mineral density are still achieved and prior bisphosphonate use should not dissuade clinicians from using teriparatide in select patients.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.